The UK and US have finalized a key trade agreement that will keep zero levies on British medicine exports being sold in the American market.
Key Provisions of the Deal
Under the terms of the agreement, the UK has agreed to boost funding on pharmaceuticals through the National Health Service (NHS). This move ensures that tariffs on these vital goods will remain at zero for a period of the next three years.
This agreement follows recent warnings to hike import taxes on branded pharmaceutical imports, with figures discussed as high as 100%.
"This deal between the Britain strengthens the worldwide climate for innovative medicines and introduces much-needed balance to American-British medicine commerce," a statement said.
Commercial Impact
Pharmaceuticals constitute one of the the United Kingdom's largest goods shipped to the America, which is easily the biggest buyer for leading UK drugmakers.
Trade data show that in the year to the end of September, the UK exported drugs valued at billions to the US. This value made up 17.4% of total UK exports in that timeframe.
"This guarantee protects work, increases capital expenditure and paves the way for the UK to emerge as a global hub for medical research," a government official commented.
Key NHS Changes
The pact involves several specific pledges from the UK:
- Price Threshold Increase: The UK will lift the affordability limit at which it considers new therapies to be unaffordable by twenty-five percent.
- Higher Drug Budget: There is a target to double total health service expenditure on treatments from 0.3% of GDP to 0.6 percent over the next decade.
- Payback Limit: The amount pharmaceutical firms must return to the NHS to stay within budget will be capped at 15%. In the past, rebates exceeded 20%.
Recent Tensions
This agreement follows a long-running row between the sector and the British authorities over drug pricing and regulatory access.
This friction were heightened by claims that US consumers were charged a premium for the identical medicines than people in the UK and Europe.
Recently, several large drug company projects in the UK have been paused or abandoned, while substantial investments have been pledged toward projects in the United States.
One official publicly accepted that the NHS had to increase expenditure on medicines, noting that its expenditure on drugs had declined as a share of its overall budget over the past decade.
